Keyword: Vertex Pharmaceuticals
Look at the last 20 years' worth of drug launches and one thing is clear: Hep C fueled some NASA-worthy blastoffs. But they're not the only ones.
Vertex has cancelled plans to test an investigational triple combo at several sites in France.
Step aside, Orkambi. Vertex’s new-and-improved cystic fibrosis med is here. It's called Symdeko, and it could add up to $200M in sales this year.
Vertex is ready to do some deals, CEO Jeffrey Leiden said Monday, and he's shopping beyond cystic fibrosis. CRISPR, for instance.
Stepped-up competition and insurer pushback aren't going away, but some are better able to handle it—and could emerge as top M&A targets.
Investors in five Big Pharmas want the companies to review whether their compensation plans effectively reward executives who hike prices.
It feels as though we say this every year, but it bears repeating: From CEOs and COOs to division chiefs and venture capital partners, women are taking the lead and making an impact all over the life sciences industry.
Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.